Effects of tranexamic acid and exogenous fibrin monomer on the liver injury area and systemic circulation in pharmacological suppression of platelet function in an experiment

Abstract

Aim. To identify and compare the morphological, hemostatic and hemostasiological consequences of intravenous administration of tranexamic acid and fibrin monomer in controlled liver injury against drug-induced thrombocytopathy.

Methods. The morphological features of fibrin formation in the area of liver injury after spontaneous bleeding arrest combined with the indicators of blood loss in the animals treated with intravenous placebo, tranexamic acid or fibrin monomer was studied in 69 male rabbits. The effects of these drugs were assessed against thrombocytopathy associated with the combined use of acetylsalicylic acid and clopidogrel. Platelet number and function (adnosine diphosphate-induced aggregation), the data of thromboelastometry and calibrated automated thrombogram, fibrinogen concentration and D-dimer level were considered in the blood test. The feature distribution in the samples was assessed using the Shapiro–Wilk test. Depending on the distribution, Student's t-test, Mann–Whitney U test or Wilcoxon signed-rank test were used to test for a significant difference between the features. Differences in mortality rate were established by using Fisher's exact test. The differences were considered statistically significant at p <0.05.

Results. A model of thrombocytopathy which showed decreased platelet aggregation function (by 4.5 times), increased blood loss (by 40%), and high mortality (53.9%) was reproduced. Only a small accumulation of thrombotic material was noted on the injured surface of such animals. The use of tranexamic acid led to decreased post-traumatic bleeding (2.5 times) and animal mortality (20%). The latter was provided on the wound surface by increasing the thickness of both thrombotic deposits and fibrin strands. When fibrin monomer was used, the phenomenon of an overcompensated decrease in blood loss (by 6.7 times) accompanied by zero mortality was noted despite a pronounced decrease in platelet aggregation. The maximum increase in the thickness of thrombotic material and fibrin strands was morphologically determined in the injury area compared with other animal groups.

Conclusion. Morphological features of traumatic hemostatic effect at the injured area when using tranexamic acid and fibrin monomer have a number of differences despite the similarity of the achieved results in minimizing blood loss.

Keywords

fibrin monomer / acetylsalicylic acid / clopidogrel / tranexamic acid / post-traumatic bleeding / hemostatic effect / fibrin formation

References

[1] Hoffman M., Monroe D.M. Coagulation 2006: a mo­dern view of hemostasis. Hematol. Oncol. Clin. North Am. 2007; 21 (1): 1–11. DOI: 10.1016/j.hoc.2006.11.004.

[2] Ho K.M., Pavey W. Applying the cell-based coa­gulation model in the management of critical bleeding. ­Anaesth. Intens. Care. 2017; 45 (2): 166–176. DOI: 10.1177/0310057X1704500206.

[3] Kuznik B.I. Kletochnye i molekuljarnye mehanizmy reguljacii sistemy gemostaza v norme i patologii. (Cellular and molecular re­gulation mechanisms of hemostasis system in health and di­sease.) Chita: Ehkspress-izdatel'stvo. 2010; 832 р. (In Russ.)

[4] Кузник Б.И. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита: Экспресс-издательство. 2010; 832 с.

[5] Kuznik B.I., Sturov V.G., Levshin N.Ju., Kudlaj D.A. Gemorragicheskie i tromboticheskie zabolevanija u detej i podrostkov. (Hemorrhagic and thrombotic diseases in childhood and adolescence.) Novosibirsk: Nauka. 2018; 5242 р. (In Russ.)

[6] Кузник Б.И., Стуров В.Г., Левшин Н.Ю., Максимова О.Г., Кудлай Д.А. Геморрагические и тромботические заболевания у детей и подростков. Новосибирск: Наука. 2018; 524 с.

[7] Panteleev M.A., Dashkevich N.M., Ataullakha­nov F.I. Hemostasis and thrombosis beyond biochemistry: roles of geometry, flow and diffusion. Thromb. Res. 2015; 136 (4): 699–711. DOI: 10.1016 / j.thromres.2015.07.025.

[8] Hoffman M.M., Monroe D.M. Rethinking the coa­gulation cascade. Curr. Hematol. Rep. 2005; 4 (5): 391–396. PMID: 16131441.

[9] Momot A.P., Vdovin V.M., Shakhmatov I.I., Tolstokorov I.G., Orekhov D.A., Shevchenko V.O., Lycheva N.A., Kudinov A.V., Belozerskaya G.G., Kiselev V.I. Systemic hemostatic and prothrombotic effects of fibrin-monomer in experiment with dosed liver therapy. ­Sibirskiy nauchnyy meditsinskiy zhurnal. 2019; 39 (1): 6–12. (In Russ.) DOI: 10.15372/SSMJ20190101.

[10] Момот А.П., Вдовин В.М., Шахматов И.И., Толстокоров И.Г., Орехов Д.А., Шевченко В.О., Лычёва Н.А., Кудинов А.В., Белозерская Г.Г., Киселёв В.И. Системные гемостатические и протромботические эффекты фибрин-мономера в эксперименте при дозированной травме печени. Сибирский науч. мед. ж. 2019; 39 (1): 6–12. DOI: 10.15372/SSMJ20190101.

[11] Vdovin V.M., Momot A.P., Orekhov D.A., Tolstoko­rov I.G., Shevchenko V.O., Krasyukova V.O., Shakhmatov I.I., Lycheva N.A., Belozerskaya G.G. Time-dependent systemic hemostatic effects of fibrin monomer in controlled liver injury in the experiment. Kazan Medical Journal. 2019; 100 (2): 257–263. (In Russ.) DOI: 10.17816/KMJ2019-257.

[12] Вдовин В.М., Момот А.П., Орехов Д.А., Толстокоров И.Г., Шевченко В.О., Красюкова В.О., Шахматов И.И., Лычёва Н.А., Белозерская Г.Г. Время-зависимые системные гемостатические эффекты фибрина-мономера при дозированной травме печени в эксперименте. Казанский мед. ж. 2019; 100 (2): 257–263. DOI: 10.17816/KMJ2019-257.

[13] Vdovin V.M., Momot A.P., Orekhov D.A., Tolstokorov I.G., Lycheva N.A., Shevchenko V.O., Shakhmatov I.I., Krasyukova V.O., Fogt E.V. Experimental study of systemic hemostatic effects of fibrin monomer in inhibition of platelet aggregation function. Bulletin of Siberian Medicine. 2020; 19 (1): 36–42. (In Russ.) DOI: 10.20538/1682-0363-2020-1-36-42.

[14] Вдовин В.М., Момот А.П., Орехов Д.А., Толстокоров И.Г., Лычёва Н.А., Шевченко В.О., Шахматов И.И., Красюкова В.О., Фохт Э.В. Системные гемостатические эффекты фибрина-мономера при ингибировании агрегационной функции тромбоцитов в эксперименте. Бюлл. сибирской мед. 2020; 19 (1): 36–42. DOI: 10.20538/1682-0363-2020-1-36-42.

[15] Hunt B.J. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015; 70 (­Suppl. 1): 50–53. DOI: 10.1111/anae.12910.

[16] Ramirez R.J., Spinella P.C., Bochicchio G.V. Tranexamic acid update in trauma. Crit. Care Clin. 2017; 33 (1): 85–99. DOI: 10.1016/j.ccc.2016.08.004.

[17] Kyoung-Jin P., Eui-Hoon K., Hee-Jin K., Sun-Hee K. Evaluation of the diagnostic performance of fibrin monomer in disseminated intravascular coagulation. Korean J. Lab. Med. 2011; 31 (3): 143–147. DOI: 10.3343/kjlm.2011.31.3.143.

[18] Momot A.P., Vdovin V.M., Orekhov D.A., Bobrov I.P., Shakhmatov I.I., Momot D.A., Belozerskaya G.G., Kuznetsova D.V., Chernus' V.E., Teryyaev V.V. Effect of exo­genous fibrin monomer on hemostatic potencial and fibrin formation in the area of controlled liver injury on the background of heparin administration in the expe­riment. Pathogenez. 2020; 18 (4): 32–42. (In Russ.) DOI: 10.25557/2310-0435.2020.04.32-42.

[19] Момот А.П., Вдовин В.М., Орехов Д.А., Бобров И.П., Шахматов И.И., Момот Д.А., Белозерская Г.Г., Кузнецова Д.В., Чернусь В.Е., Теряев В.В. Влияние экзогенного фибрина-мономера на гемостатический потенциал и фибринообразование в области дозированной травмы печени на фоне введения гепарина в эксперименте. Патогенез. 2020; 18 (4): 32–42. DOI: 10.25557/2310-0435.2020.04.32-42.

[20] Rukovodstvo po provedeniu doklinicheskih issledovaniy lekarstvenih sredstv. Chast' pervaja. (Guidelines for preclinical drug trial. Part 1.) Ed. by A.N. Mironova. M.: Grif and K. 2012; 472–473. (In Russ.)

[21] Руководство по проведению доклинических исследований лекарственных средств. Часть первая. Под ред. А.Н. Миронова. М.: Гриф и К. 2012; 472–473.

[22] Ziganshin A.U. New antiaggregants — blockers of platelet Р2-receptors. Kazan Medical Journal. 2010; 91 (1): 73–79. (In Russ.)

[23] Зиганшин А.У. Новые антиагреганты — блокаторы тромбоцитарных Р2-рецепторов. Казанский мед. ж. 2010; 91 (1): 73–79.

[24] Zerbino D.D., Lukasevich L.L. Disseminirovannoe vnutrisosudistoe svertyvanie krovi: fakty i koncepcii. (Disseminated intravascular coagulation: facts and concepts.) M.: Meditsina. 1989; 256 р. (In Russ.)

[25] Зербино Д.Д., Лукасевич Л.Л. Диссеминированное внутрисосудистое свёртывание крови: факты и концепции. М.: Медицина. 1989; 256 с.

[26] Vdovin V.M., Bobrov I.P., Shakhmatov I.I., Momot A.P. Morphological consequences of systemic application of fibrin monomer in conditions of hemostatic potential suppression and fibrinolytic potential amplification in dosed liver injury in experiment. Byulleten' meditsinskoy nauki. 2021; (1): 74–87. (In Russ.)

[27] Вдовин В.М., Бобров И.П., Шахматов И.И., Момот А.П. Морфологические последствия системного применения фибрин-мономера в условиях подавления гемостатического и усиления фибринолитического потенциалов при дозированной травме печени в эксперименте. Бюлл. мед. науки. 2021; (1): 74–87.

[28] Federal'noe rukovodstvo po ispol'zovaniju lekarstvennyh sredstv (formuljarnaja sistema). (Fe­deral guidelines on the use of medicines (formulary system).) Ed. by A.G. Chuchalin, A.L. Hohlov. Vol. XVIII. М.: Vidoks. 2017; 471–790. (In Russ.)

[29] Федеральное руководство по использованию лекарственных средств (формулярная система). Под ред. А.Г. Чучалина, А.Л. Хохлова. Выпуск XVIII. М.: Видокс. 2017; 471–790.

[30] Adams S.A., Kelly S.L., Kirsch R.E., Robson S.C., Shephard E.G. Role of neutrophil membrane proteases in fibrin degradation. Blood Coagul. Fibrinolysis. 1995; 6: 693–702. DOI: 10.1097/00001721-199512000-00001.

[31] Bach-Gansmo E.T., Halvorsen S., Godal H.C., Skjonsberg O.H. D-dimers are degraded by human neutrophil elastase. Thromb. Res. 1996; 82 (2): 177–186. DOI: 10.1016/0049-3848(96)00064-3.

RIGHTS & PERMISSIONS

Eco-Vector